<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01170845</url>
  </required_header>
  <id_info>
    <org_study_id>531</org_study_id>
    <nct_id>NCT01170845</nct_id>
  </id_info>
  <brief_title>Effect of Neutrophil Elastase Inhibitor on Lung Injury After Esophagectomy</brief_title>
  <acronym>NEIE</acronym>
  <official_title>A Pilot Study of Effect of Neutrophil Elastase Inhibitor on Lung Injury After Esophagectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yokohama City University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yokohama City University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A neutrophil elastase inhibitor may have effect on suppression of the lung injury after
      thoransthoracic esophagectomy. The investigators hypothesized that postoperative
      complication, particularly respiratory complication may be reduced by neutrophil elastase
      inhibitor after esophagectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study was to clarify the usefulness of perioperative administration of
      sivelestat sodium hydrate, a selective inhibitor of neutrophil elastase in the pulmonary
      function, systemic inflammatory response, and the postoperative clinical course following
      video-assisted thoracoscopic esohpagectomy for esophageal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>9 days</time_frame>
    <description>the arterial oxygen pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>9 days</time_frame>
    <description>fraction of inspired oxygen ratio (PF ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>9 days</time_frame>
    <description>the duration of mechanical ventilation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the control group received saline for 7 days starting at the beginning of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the S group received sivelestat sodium hydrate at a dosage 4.8mg/kg/day for 7 days starting at the beginning of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sivelestat sodium hydrate</intervention_name>
    <description>saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>S group</arm_group_label>
    <other_name>Elaspol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Thoracic esophageal squamous cell carcinoma

        Exclusion Criteria:

          -  Preoperative chemoradiotherapy

          -  Cardiovascular disease with NYHA grade III or IV

          -  Pulmonary disorder with Hugh-Jones classification II, III, IV, or V, preo

          -  Liver cirrhosis

          -  Renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>77 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chikara Kunisaki, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Yokohama City University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chikara Kunisaki</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2010</study_first_submitted>
  <study_first_submitted_qc>July 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2010</study_first_posted>
  <last_update_submitted>July 26, 2010</last_update_submitted>
  <last_update_submitted_qc>July 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Institutional Review Board</name_title>
    <organization>Yokohama City University, Medical Center</organization>
  </responsible_party>
  <keyword>Esophagectomy</keyword>
  <keyword>Postoperative respiratory complications</keyword>
  <keyword>neutrophil elastase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sivelestat</mesh_term>
    <mesh_term>Proteinase Inhibitory Proteins, Secretory</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

